Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: ataluren, mt-3724, zolimomab aritox +2 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 223 | 0.85 |
| pathways Reactome | 16 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 10950
Sealed predictions
- RPL23 in dopamine neurons, braak+0.43 (p 0.253) → +0.29 (p 0.457)receipt 10957
Swarm cases
receipt 10957: RPL23 in dopamine neurons, braak
- power
- full sample +0.33 (p 0.179, n 18), 95% CI -0.16 to +0.69. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.29 (p 0.235, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.39 (p 0.111, n 18). could be the mix.
- skeptic
- leave-one-out range +0.25 to +0.47, sign flips 0; without severely affected donors +0.33 (p 0.179, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RPL23 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts